Navigation Links
Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine),Clinical Data at the Annual NCDEU Meeting

PALO ALTO, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it will present at the 47th Annual NCDEU Meeting the results of a Phase I clinical trial of Staccato loxapine (AZ-004), which is being developed for the treatment of acute agitation in patients with schizophrenia. The annual NCDEU meeting is co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology.

The poster presentation, "Novel inhalation technology delivers intravenous-like pharmacokinetics of loxapine in healthy volunteers" (Session 1-93), will be available for viewing at the meeting at the Mizner Center in Boca Raton, Florida on Tuesday, June 12, 2007 from 12:00 to 2:00 pm.

Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has five product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.

CONTACT: Thomas B. King, Pesident & CEO of Alexza Pharmaceuticals, Inc.,+1-650-687-3900, tking@alexza.com

Web site: http://www.alexza.com/

Ticker Symbol: (NASDAQ-NMS:ALXA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at the American Headache Society Meeting
2. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Md. , March 27, 2017  ImMAGE Biotherapeutics ... its immunotherapy successfully passed early toxicology and efficacy studies. ... system to target a specific protein, MAGE A, in ... negative breast cancer. After 4 weeks ... able to show very little toxicity in a full ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board ... of Integrative Medicine and available for application on Saturday, May 27, 2017, following ... in Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... Perry, GA (PRWEB) , ... March 28, 2017 , ... ... headquarters to Marshallville, Georgia, in early March. , The seed processing plant opened in ... the location since 2016. The new office allows opportunity for transition of Patten Seed ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common and ... Advanced Dermatology has a lot to offer to the discussion of dealing with ... news is that there are many home remedies that can help remove the oily shine ...
Breaking Medicine News(10 mins):